The biopharmaceutical company Lipum specializes in the discovery and development of novel drugs to treat diseases related to chronic inflammation. The company has developed its first candidate drug in collaboration with the SciLifeLab Drug Discovery and Development Platform and developed a new type of analysis assay with the SciLifeLab Affinity Proteomics-Uppsala Unit, belonging to the Clinical Proteomics and Immunology Platform.
Industry case: With support from two SciLifeLab service areas, Lipum AB develops a biomarker assay to support the development of a novel drug for chronic inflammation
